Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified ...

The average one-year price target for Cassava Sciences (NasdaqCM:SAVA) has been revised to $5.10 / share. This is an increase ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 83.9% over the past four weeks. However, given the fact that it is now in ...

Cassava Sciences (SAVA) has quickly become the subject of renewed attention after CEO Richard Barry put his own money on the line. Just weeks after halting the company’s long-running Alzheimer’s ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study for ...

Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher Tuesday morning after a Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each. What To Know ...

Pacific has been near the bottom of the WCC standings for most of the season, so the Tigers weren't expected to put up much ...

ANN ARBOR, MI -- Sitting by a creek, listening to water flow with a bottle of wine and a blanket, or dining inside a charming, rustic barn is what Sava Farah envisions for her new restaurant. The ...